Achieve Life Sciences Announces Closing Of Merger With OncoGenex Pharmaceuticals

Achieve Life Sciences has announced the closing of its merger with OncoGenex Pharmaceuticals, as a result of which the stockholders of Achieve have become the majority stockholders of Oncogenex. Since then, the employees of both companies have combined to move forward together, and Oncogenex has been renamed to Achieve Life Sciences.

Achieve continues to focus on the development of its smoking cessation drug, Cytisine. Cytisine is a plan-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. The drug has been successful in Europe and New Zealand, and the company plans to begin a placebo-controlled Phase . . .